Search research articles
Contact Us
Filters
Showing results (151-160 of 269) with videos related to
Page
of 27
Sort By:
Journal for Immunotherapy of Cancer
|
October 19, 2023
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
Analena Handke, Claudia Kesch, Wolfgang Peter Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 15, 2021
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease
Francesco Barbato, Wolfgang Peter Fendler, Isabel Rauscher, et al.
Diagnostics (Basel, Switzerland)
|
January 5, 2021
MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients
Tibor Szarvas, Michèle J Hoffmann, Csilla Olah, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 8, 2018
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
Ali Afshar-Oromieh, Nils Debus, Monika Uhrig, et al.
International Journal of Molecular Sciences
|
July 24, 2021
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
Magdalena Staniszewska, Pedro Fragoso Costa, Matthias Eiber, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 24, 2020
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Robert Seifert, Katharina Kessel, Katrin Schlack, et al.
BMC Cancer
|
May 8, 2021
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
Jeremie Calais, Shaojun Zhu, Nader Hirmas, et al.
Cancer Immunology, Immunotherapy : CII
|
November 17, 2022
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Ádám Széles, Tamás Fazekas, Szilard Váncsa, et al.
Clinical Genitourinary Cancer
|
September 23, 2025
Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer
Dániel Juhász, Anita Csizmarik, Melinda Váradi, et al.
Urologie (Heidelberg, Germany)
|
August 12, 2024
[Risk-adapted early detection program for prostate cancer 2.0-position paper of the German Society of Urology 2024]
Maurice Stephan Michel, Jürgen E Gschwend, Bernd Wullich, et al.
Page
of 27
Search research articles
Search
Showing results (151-160 of 269) with videos related to
Sort By:
Page
of 27
Journal for Immunotherapy of Cancer
|
October 19, 2023
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
Analena Handke, Claudia Kesch, Wolfgang Peter Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 15, 2021
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease
Francesco Barbato, Wolfgang Peter Fendler, Isabel Rauscher, et al.
Diagnostics (Basel, Switzerland)
|
January 5, 2021
MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients
Tibor Szarvas, Michèle J Hoffmann, Csilla Olah, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 8, 2018
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
Ali Afshar-Oromieh, Nils Debus, Monika Uhrig, et al.
International Journal of Molecular Sciences
|
July 24, 2021
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
Magdalena Staniszewska, Pedro Fragoso Costa, Matthias Eiber, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 24, 2020
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Robert Seifert, Katharina Kessel, Katrin Schlack, et al.
BMC Cancer
|
May 8, 2021
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
Jeremie Calais, Shaojun Zhu, Nader Hirmas, et al.
Cancer Immunology, Immunotherapy : CII
|
November 17, 2022
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Ádám Széles, Tamás Fazekas, Szilard Váncsa, et al.
Clinical Genitourinary Cancer
|
September 23, 2025
Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer
Dániel Juhász, Anita Csizmarik, Melinda Váradi, et al.
Urologie (Heidelberg, Germany)
|
August 12, 2024
[Risk-adapted early detection program for prostate cancer 2.0-position paper of the German Society of Urology 2024]
Maurice Stephan Michel, Jürgen E Gschwend, Bernd Wullich, et al.
Page
of 27